Login / Signup

Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.

Christian P LarsenFlavio VincentiTzuyung D KouCraig A ShadurBarbara BresnahanStanley C JordanE Steve WoodleNelson GoesJohn VellaDavid WojciechowskiMartin S PolinskyAndres Gomez-Caminero
Published in: Transplantation direct (2024)
Our results from the ENLiST registry, a large, prospective real-world study, showed that the incidence rates of PTLD and CNS PTLD in belatacept-treated EBV-seropositive transplant recipients were consistent with findings from previous phase 3 trials.
Keyphrases
  • epstein barr virus
  • diffuse large b cell lymphoma
  • clinical practice
  • risk factors